Shares of Horizon Therapeutics PLC (NASDAQ:HZNP) have earned an average recommendation of "Buy" from the sixteen ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $74.00.
A number of research firms have recently weighed in on HZNP. Piper Sandler raised their price target on shares of Horizon Therapeutics from $61.00 to $90.00 and gave the company an "overweight" rating in a report on Wednesday, July 22nd. BMO Capital Markets raised their price target on shares of Horizon Therapeutics from $70.00 to $105.00 and gave the company an "outperform" rating in a report on Thursday, August 6th. Citigroup began coverage on shares of Horizon Therapeutics in a report on Thursday, August 27th. They set a "buy" rating and a $112.00 price target on the stock. BidaskClub upgraded shares of Horizon Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Friday. Finally, Bank of America raised their price target on shares of Horizon Therapeutics from $92.00 to $95.00 and gave the company a "buy" rating in a report on Monday, August 17th.
In other news, Director Michael G. Grey sold 1,755 shares of the company's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total value of $96,525.00. Following the completion of the transaction, the director now owns 1,755 shares in the company, valued at $96,525. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Barry Moze sold 23,158 shares of the company's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $54.64, for a total transaction of $1,265,353.12. Following the completion of the transaction, the executive vice president now owns 145,242 shares of the company's stock, valued at approximately $7,936,022.88. The disclosure for this sale can be found here. Insiders sold 186,018 shares of company stock valued at $13,042,766 in the last ninety days. Insiders own 4.30% of the company's stock.
Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Horizon Therapeutics by 1.2% in the second quarter. Vanguard Group Inc. now owns 17,754,535 shares of the biopharmaceutical company's stock valued at $986,797,000 after buying an additional 209,759 shares during the period. FMR LLC boosted its holdings in Horizon Therapeutics by 22.1% during the second quarter. FMR LLC now owns 7,288,468 shares of the biopharmaceutical company's stock worth $405,093,000 after purchasing an additional 1,317,555 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Horizon Therapeutics by 13.7% during the first quarter. Janus Henderson Group PLC now owns 6,682,922 shares of the biopharmaceutical company's stock worth $197,948,000 after purchasing an additional 807,303 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Horizon Therapeutics by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,134,098 shares of the biopharmaceutical company's stock worth $122,451,000 after purchasing an additional 389,654 shares during the last quarter. Finally, Orbimed Advisors LLC boosted its holdings in Horizon Therapeutics by 22.5% during the second quarter. Orbimed Advisors LLC now owns 2,867,910 shares of the biopharmaceutical company's stock worth $159,398,000 after purchasing an additional 526,210 shares during the last quarter. Institutional investors own 89.17% of the company's stock.
Shares of NASDAQ:HZNP opened at $79.93 on Monday. The firm has a fifty day moving average of $71.31 and a two-hundred day moving average of $49.67. The firm has a market capitalization of $16.50 billion, a P/E ratio of 32.76, a price-to-earnings-growth ratio of 1.02 and a beta of 1.22. Horizon Therapeutics has a 12-month low of $23.81 and a 12-month high of $81.18. The company has a quick ratio of 1.45, a current ratio of 1.51 and a debt-to-equity ratio of 0.42.
Horizon Therapeutics (NASDAQ:HZNP) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.36 by $0.04. The company had revenue of $462.80 million during the quarter, compared to analyst estimates of $333.70 million. Horizon Therapeutics had a net margin of 34.09% and a return on equity of 19.67%. The company's revenue for the quarter was up 44.4% on a year-over-year basis. During the same quarter last year, the business posted $0.49 EPS. Equities research analysts expect that Horizon Therapeutics will post 2.6 earnings per share for the current fiscal year.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
See Also: How to execute a trade ex-dividend strategy?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Gold Stocks to Buy Before the Fed Changes Its Mind
Just when investors thought that the price of gold couldn’t go any higher, the Federal Reserve added fuel to the fire. On July 29, the Fed said there was not sufficient evidence of an economic recovery to warrant changing their current policies.
Not only does that mean that interest rates will stay at or nor zero, but that the Fed may initiate other actions as well. In his statement after the Fed meeting, chairman Jerome Powell said the Fed was “not even thinking about thinking about raising rates.”
And while the novel coronavirus was certainly a factor, it’s not the only factor. The Fed is looking intently at the collateral damage from the lockdown measures in March and April. Over 14 million Americans who had jobs in February are unemployed. And many of those jobs will not be coming back.
This is creating the perfect scenario for gold and gold stocks. The price of gold has surged over 25% in 2020. At the time of this writing, it sits at $1,953 per ounce. Of course as soon as gold starts to near $2,000 the cries that the rally is over begin.
Are they right again? Maybe, but I’m a little skeptical. Gold always climbs during times of uncertainty. That’s true today more than ever. We’re months away from a presidential election. We’re learning how to live with a novel virus for which there is no vaccine. We have social unrest that has turned into riots in many major cities.
With that in mind, here are seven of the best gold stocks that you can invest in right now.
View the "7 Gold Stocks to Buy Before the Fed Changes Its Mind".